- Direction
- Unknown
- Own history
- —
- Peers
- 27th
- Persistence
- TRANSIENT
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAclaris Therapeutics, Inc.'s latest supported as-filed period reports revenue of $1.6M; gross margin moved 1560 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
Separate current dimensions—not a universal score or investment ranking.
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Capital expenditure increased 176.2%; Capex / revenue moved 238 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 24.5%; Operating cash flow decreased 98.6%.
2 evidence-backed componentsFree-cash-flow proxy changed -98.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ACRS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-119231SEC ↗8-KOct 27, 2026Period Oct 27, 20260001104659-26-118952SEC ↗8-KAug 6, 2026Period Aug 6, 20260001104659-26-092128SEC ↗10-QAug 6, 2026Period Jun 30, 20260001104659-26-092065SEC ↗8-KAug 6, 2026Period Aug 6, 20260001104659-26-091629SEC ↗4Aug 4, 2026Period Aug 1, 20260002076327-26-000006SEC ↗4Jun 8, 2026Period Jun 4, 20260001590102-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 1, 2026Filed Aug 4, 2026 | Kolbeck Roland WilhelmChief Scientific Officer | Option ExerciseDirect | 36,375 | — | — | Form 4 ↗ |
| Aug 1, 2026Filed Aug 4, 2026 | Kolbeck Roland WilhelmChief Scientific Officer | Tax WithholdingDirect | 12,385 | $5 | $64,402 | Form 4 ↗ |
| Aug 1, 2026Filed Aug 4, 2026 | Kolbeck Roland WilhelmChief Scientific Officer | Option ExerciseDirect | 36,375 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Capital expenditure changed +176.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Operating cash flow changed -98.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Gross margin changed +1560 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating margin changed -45200 basis points from the comparable as-filed period.
Operating income changed -31.7% from the comparable as-filed period.
Research & development changed +57.8% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001172252-26-000002